Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SaROD: Shorter Ocrelizumab Infusions in MS
NCT03606460Phase 3Completed
- Sponsor
- Genentech
- Start
- Sep 2018
- Primary completion
- May 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label trial of ocrelizumab in primary progressive multiple sclerosis (PPMS) and multiple sclerosis (MS) (2 cohorts), sponsored by Genentech. Primary endpoint: Percentage of Participants With Infusion-related Reaction (IRR) Treated With 600 mg IV Ocrelizumab at 24 hours. Started Sep 2018; status: completed.
02
Drugs
ocrelizumab
03
Conditions
primary progressive multiple sclerosis (PPMS)multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT03606460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03606460.